FDA OKs Genzyme's Renvela (TheStreet.com)
It plans to launch the drug for dialysis patients in the U.S. during the first quarter of next year.

(AFX UK Focus) 2007-10-22 15:36 GMT: Genzyme's Renvela gets FDA approval for dialysis patients (Interactive Investor)
BOSTON (Thomson Financial) - Genzyme Corp. said Monday the Food and Drug Administration has approved the company's Renvela drug for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

APP Receives Two FDA Approvals For Fludarabine Phosphate (Medical News Today)
Abraxis Pharmaceutical Products (APP), the hospital-based business of Abraxis BioScience, Inc. (NASDAQ:ABBI), announced two approvals from U.S. Food and Drug Administration (FDA) to market the liquid and lyophilized versions of Fludarabine phosphate. [click link for full article]